Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07569692

PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Evaluated by CoroNary Computed Tomography Angiography-2

The PREVENT-2 trial is to determine whether an initial invasive strategy-consisting of early coronary angiography (CAG) with intent for preventive percutaneous coronary intervention (PCI) in addition to optimal medical therapy (OMT)-reduces the incidence of the primary composite outcome of cardiac death, target-vessel myocardial infarction (MI), unplanned urgent revascularization, or hospitalization for unstable or progressive angina at 3 years, compared with an initial conservative strategy of optimal medical therapy (OMT) alone, in patients with high-risk vulnerable plaque identified by coronary computed tomography angiography (CCTA).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Asan Medical Center

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged ≥18 years
  • Patients with suspected coronary artery disease (CAD) (e.g., chest pain syndrome or equivalent symptoms) who are evaluated with coronary computed tomography angiography (CCTA)
  • Coronary computed tomography angiography (CCTA) showing:

Plaque with at least moderate stenosis in one or more major epicardial coronary arteries; and

At least two high-risk plaque (HRP) feature at the site of stenotic lesions, defined as any of the following:

  • Low-attenuation plaque (LAP) (<70 Hounsfield units)
  • Positive remodeling (PR) (remodeling index >1.2)
  • Napkin-ring sign (NRS)
  • Spotty calcification (SC) (<3 mm in length)
  • Willing and able to provide written informed consent

Exclusion criteria

  • Acute coronary syndrome (ACS) requiring urgent or emergent invasive evaluation
  • Hemodynamically unstable conditions
  • Significant left main coronary artery disease (≥50% diameter stenosis)
  • Coronary anatomy unsuitable for either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
  • Left ventricular ejection fraction (LVEF) <35%

→ Left ventricular ejection fraction <35%

  • New York Heart Association (NYHA) class III or IV heart failure at entry or hospitalization for exacerbation of chronic heart failure within the previous 6 months
  • Prior coronary artery bypass grafting (CABG)
  • Severe renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m²) or end-stage renal disease on dialysis
  • Contraindication to undergoing coronary computed tomography angiography (CTA) (e.g., allergy to radiographic contrast that cannot be adequately premedicated, any prior anaphylaxis to radiographic contrast, or inability to cooperate with scan acquisition)
  • Contraindications to or planned discontinuation of dual antiplatelet therapy within 1 year
  • Life expectancy less than the duration of the trial due to non-cardiovascular comorbidity
  • Planned cardiac or major noncardiac surgery within the study period
  • Women who are breastfeeding, pregnant, or planning to become pregnant during the course of the study
  • Inability to comply with the study protocol
  • Active participation in another interventional clinical trial involving an unapproved investigational drug or device

Treatment and study plan

Initial Invasive Strategy

Procedure

Invasive coronary angiography (CAG) within 30 days after randomization, with the intent to perform preventive percutaneous coronary intervention (PCI) in addition to optimal medical therapy (OMT).

For further detailed assessment of vulnerable plaque lesions detected by coronary computed tomography angiography, the use of intracoronary imaging modalities (near-infrared spectroscopy, optical coherence tomography, or intravascular ultrasound) will be strongly recommended.

Initial Conservative Strategy

Drug

Optimal medical therapy (OMT) alone, with invasive coronary angiography (CAG) reserved only for failure of optimal medical therapy, defined as recurrent or worsening symptoms despite maximally tolerated medical therapy, or the occurrence of an acute coronary event.

Primary outcomes

  1. The event rate of Composite of death from cardiac causes, target-vessel myocardial infarction, unplanned urgent revascularization, or hospitalization for unstable or progressive angina at 3 years after randomization.

    Time frame: 3 years

Secondary outcomes

  1. The event rate of Individual components of the primary composite outcome

    Time frame: 3 years

    death from cardiac causes, target-vessel myocardial infarction, unplanned urgent revascularization, or hospitalization for unstable or progressive angina at 3 years after randomization.

  2. The event rate of Death (all-cause, cardiac, or non-cardiac causes)

    Time frame: 3 years

  3. The event rate of Myocardial Infarction (any, periprocedural or spontaneous; target-vessel or non-target-vessel)

    Time frame: 3 years

  4. The event rate of Revascularization (any, target-vessel, non-target-vessel)

    Time frame: 3 years

  5. The event rate of Unplanned hospitalization for unstable or progressive angina

    Time frame: 3 years

  6. The event rate of Hospitalization (any, cardiac or noncardiac causes)

    Time frame: 3 years

  7. The event rate of Stent thrombosis (definite or probable)

    Time frame: 3 years

  8. The event rate of stroke (any, ischemic, or hemorrhagic)

    Time frame: 3 years

  9. The event rate of Bleeding events (Bleeding Academic Research Consortium (BARC) criteria)

    Time frame: 3 years

  10. The event rate of Procedural complications requiring active intervention related to Percutaneous coronary intervention

    Time frame: 3 years

  11. Patient-oriented composite outcome (POCO) (a composite of all-cause death, all myocardial infarction, or any repeat revascularization)

    Time frame: 3 years

  12. Change in Angina-related quality of life (assessed by the Seattle Angina Questionnaire [SAQ])

    Time frame: Baseline, 6 months, 1 year, 2 years, and 3 years

  13. Economic evaluation of healthcare resource use, costs, and cost-effectiveness

    Time frame: From baseline to 3 years; assessed at 1 month, 6 months, 1 year, 2 years, and 3 years

    Healthcare resource utilization (including hospitalizations, procedures, and outpatient visits) will be collected and used to estimate total healthcare costs. Cost-effectiveness will be assessed using the incremental cost-effectiveness ratio (ICER), expressed as cost per quality-adjusted life year (QALY) gained. These components will be analyzed within a unified economic evaluation framework.

Study contacts

Contact information is provided by the study sponsor or research team.

Duk-woo Park Professor in Department of Cardiology, Asan Medical Center, MD, PhD

CONTACT

[email protected]

82-2-3010-4812

Sponsors and collaborators

Lead sponsor

Seung-Jung Park

Other

Collaborators

  • CardioVascular Research Foundation, Korea

Registry information

Official study title

A Comparison of Initial Invasive Strategy and Initial Conservative Strategy for the Treatment of Vulnerable Atherosclerotic Coronary Plaques Identified by Coronary CT Angiography

Acronym: PREVENT-2

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
May 6, 2026
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.